Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2009 | Original Article

Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy

Authors: Kouichi Momiyama, Hidenari Nagai, Yasukiyo Sumino

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Abstract

Purpose

It is known that tumors develop mechanisms to escape from the immune system and to inhibit antitumor responses. The aim of this study was to retrospectively assess changes of host immunity in relation to efficacy in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by combined intra-arterial chemotherapy.

Methods

Thirty-seven adult Japanese LC patients with aHCC were treated by intra-arterial combination chemotherapy. The control group was composed of 19 adult Japanese patients with chronic hepatitis C diagnosed by pathological examination of liver biopsy specimens. All control patients were stage 1 according to the fibrosis score of Desment.

Results

Ten of the 37 patients (group PR) showed a partial response and 17 of the 37 patients (group SD) showed stable disease, but 10 of the 37 patients (group PD) showed no response. There were no significant differences in the percentage of Th1 cells between any of the groups either before or after chemotherapy. The percentage of Th2 cells was significantly higher in group PD before and after chemotherapy than in the control group (P < 0.05 by Tukey’s test). Although there was no significant difference, the percentage of Th2 cells was higher in group SD than in group PR.

Conclusions

The percentage of Th2 cells increased in LC patients with aHCC as the efficacy of intra-arterial combination chemotherapy decreased. These results indicated that intra-arterial chemotherapy might be not useful for patients with aHCC, because it induces Th2 dominant host immunity.

Okuda K, Fujimoto I, Hanai A, Urano Y (1987) Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47:4967–4972PubMed

Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics. CA Cancer J Clin 48:6–29PubMedCrossRef

El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef

Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC (1997) Increase in primary liver cancer in the UK 1979–1994. Lancet 350:1142–1143PubMedCrossRef

Deuffic S, Poynard T, Buffat L, Valleron AJ (1998) Trends in primary liver cancer. Lancet 351:214–215PubMedCrossRef

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef

Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465PubMedCrossRef

Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393PubMed

Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295–299PubMedCrossRef

10.

Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai T, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 3:1719–1722

11.

Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Tanikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6:587–591PubMed

12.

Nagai H, Matsui T, Kanayama M, Momiyama K, Ikoma A, Okano N, Ikehara T, Matsumaru K, Watanabe M, Iida K, Ishii K, Sumino Y, Miki K (2007) Assessment of combined intra-arterial low-dose 5-fluorouracil, cisplatin, and leucovolin chemotherapy for patients with advanced hepatocellular carcinoma using the Japan integrated staging score. J Med Soc Toho 54:21–28

13.

Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280–284PubMed

14.

Kobayashi M, Kobayashi H, Pollard RB, Suzuki F (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869–5873PubMed

15.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97PubMedCrossRef

16.

Hu H-M, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from type 2 to a type 1 cytokine profile. J Immunol 161:3033PubMed

17.

Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S (2001) Expression of Fas/Fas ligand and its involvement in infiltrating lymphocytes in hepatocellular carcinoma. J Gastroenterol 36:681–688PubMedCrossRef

18.

Yakirevich E, Lefel O, Sova Y, Stein A, Cohen O, Izhak OB, Resnick MB (2002) Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J Pathol 196:67–75PubMedCrossRef

19.

Ikeguchi M, Oi K, Hirooka Y, Kaibara N (2004) CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur J Surg Oncol 30:53–57PubMedCrossRef

20.

Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef

21.

Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41:722–730PubMedCrossRef

22.

Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457–2464PubMedCrossRef

23.

Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y (2006) Increase of CD4+ CD25+ regulatory T cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45:254–262PubMedCrossRef

24.

Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K (2008) Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother Pharmacol Feb 8. [Epub ahead of print]

25.

[25] Iwamiya T, Sawada S, and Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994;33(Suppl):S134–S138

26.

Shinohara M, Ishii K, Takamura N (2003) Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response no response to IFN. Hepatol Res 27:260–265PubMedCrossRef

27.

Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197–207PubMedCrossRef

28.

Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef

29.

Gabrilovich D (2004) Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev Immunol 4:941–952PubMedCrossRef

30.

Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL (2002) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 8:1787–1793PubMed

31.

Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A et al (2003) Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89:1463–1472PubMedCrossRef

32.

Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–490PubMed

33.

Ishida T, Oyama T, Carbone DP, Gabrilovich DI (1998) Defective function of langerhans cells in tumor-bearing animals is the results of defective maturation from hemopoietic progenitors. J Immunol 161:4842–4851PubMed

34.

Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M et al (2006) Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 12:3275–3282PubMed

35.

Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5:2963–2970PubMed

36.

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cell and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166PubMed

37.

Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI (1999) Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 163:3260–3268PubMed

38.

Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY (1998) Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778–4791PubMed

39.

Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Fogli M, Oliviero B, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230–237PubMedCrossRef

40.

Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, Kamimura D, Ueda N, Iwakura Y, Ishihara K, Murakami M, Hirano T (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173:3844–3854PubMed

41.

Yang AS, Lattime EC (2003) Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63:2150–2157PubMed

42.

Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154:1280–1286PubMed

43.

Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH (2002) CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99:2468–2476PubMedCrossRef

44.

Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef

45.

Ferrara N, Gerber HP, LeCounter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

46.

Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341PubMedCrossRef

47.

Matsui T, Nagai H, Sumino Y, Miki K (2008) Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis. Cancer Chemother Pharmacol 62:401–406PubMedCrossRef

Title: Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy
Authors: Kouichi Momiyama
Hidenari Nagai
Yasukiyo Sumino
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0866-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2009

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study

A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer